Brought to you by

Chronogen licenses aging targets from McGill University
17 Dec 2003
Executive Summary
Canadian drug discovery company Chronogen (drugs for age-dependent diseases) has obtained an exclusive worldwide license to certain age-dependent proteins and targets from McGill University.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Concluded
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com